Novo Nordisk has filed a New Drug Application with the Food and Drug Admistration for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight in adults with obesity, or who are overweight with comorbidities. The emerging evidence indicates that GLP-1 reduce hunger-driven feeding, the hedonic value of food and food-motivation. Further, there is some evidence that the effect of GLP-1 on reward behavior is not limited to food-related reward but also extends to cocaine, amphetamine and alcohol reward. See review. In a clinical trial, at 2 years patients on liraglutide lost 3 kg more weight than those on orlistat. The two year prevalence of prediabetes was reduced by 52% and the metabolic syndrome by 59% with improvements in blood pressure an lipids.
Also, Orexigen Therapeutics Inc. has resubmitted it New Drug Application to the FDA for its anti-obesity compound, Contrave. In November, Orexigen submitted results from a study requested by the FDA to rule out major adverse cardiovascular events. The company has expressed confidence that Contrave with will be approved by the FDA next year in the US and in Europe as well.